去纤维钠的用法与用量

It was approved by the U.S. Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016. The trade name is Defitelio, also known as defibrinoside. Defibrotide is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Usage and dosage of defibrinated sodium:

The dose of defibrotide (Defibrotide) should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Both adults and children can be treated with defibrinated sodium, which should be diluted before infusion. The recommended dose is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. Administer defibrinated sodium for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days.

Prior to administration of defibrinated sodium, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Administer defibrinated sodium by constant intravenous infusion over a 2-hour period. Use an infusion set equipped with a 0.2 micron in-line filter to administer the diluted defibrinated sodium (defibrotide) solution. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration. Do not coadminister defibrotide sodium with other intravenous drugs at the same time and in the same intravenous line.

Concurrent use with a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide (defibrotide) therapy, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.